ASBP (Aspire-Lakewood Holdings) 3-Year EPS without NRI Growth Rate: -214.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASBP Aspire-Lakewood Holdings Inc ASBP
11 GF Score
Price $9.25
! 2 Warning Signs
View Full Analysis

What is Aspire-Lakewood Holdings 3-Year EPS without NRI Growth Rate?

Aspire-Lakewood Holdings ASBP +2.42% 11 3-Year EPS without NRI Growth Rate is -214.00% as of Jun. 2026. GuruFocus rates ASBP with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Aspire-Lakewood Holdings ranks worse than 99.83% on this metric.

Aspire-Lakewood Holdings's EPS without NRI for the three months ended in Jun. 2026 was $-2.30.

During the past 3 years, the average EPS without NRI Growth Rate was -214.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Aspire-Lakewood Holdings was -214.00% per year. The lowest was -214.00% per year. And the median was -214.00% per year.


Aspire-Lakewood Holdings  (NAS:ASBP) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Aspire-Lakewood Holdings 3-Year EPS without NRI Growth Rate Related Terms


ASBP vs PDSB, KPRX, SNTI: 3-Year EPS without NRI Growth Rate Comparison

For the Biotechnology subindustry, Aspire-Lakewood Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspire-Lakewood Holdings 3-Year EPS without NRI Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aspire-Lakewood Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aspire-Lakewood Holdings's 3-Year EPS without NRI Growth Rate falls into.


ASBP
11GF Score
Aspire-Lakewood Holdings Inc ASBP
3-Year EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspire-Lakewood Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

What does a 3-Year EPS without NRI Growth Rate of -214.00% mean?
Aspire-Lakewood Holdings (ASBP) has a 3-Year EPS without NRI Growth Rate of -214.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aspire-Lakewood Holdings and its competitors. According to the industry distribution chart, Aspire-Lakewood Holdings ranks #1158 out of 1160 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Aspire-Lakewood Holdings' 3-Year EPS without NRI Growth Rate too high?
Aspire-Lakewood Holdings' current 3-Year EPS without NRI Growth Rate is -214.00%. Based on the distribution chart, Aspire-Lakewood Holdings ranks #1158 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aspire-Lakewood Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Aspire-Lakewood Holdings' 3-Year EPS without NRI Growth Rate compare to PDSB and KPRX?
According to the Biotechnology industry distribution chart, Aspire-Lakewood Holdings ranks #1158 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Aspire-Lakewood Holdings in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aspire-Lakewood Holdings and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspire-Lakewood Holdings's current 3-Year EPS without NRI Growth Rate is -214.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspire-Lakewood Holdings stock overvalued right now?
Aspire-Lakewood Holdings (ASBP) has a current 3-Year EPS without NRI Growth Rate of -214.00%. The current 3-Year EPS without NRI Growth Rate is -214.00%. Aspire-Lakewood Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Aspire-Lakewood Holdings (ASBP), the current 3-Year EPS without NRI Growth Rate is -214.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aspire-Lakewood Holdings Business Description

Address 23150 Fashion Drive, Suite 232, Estero, FL, USA, 33928
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
11GF Score

Get the complete analysis for ASBP

3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.25
Price